Chemoresistance is one of the biggest hurdles while treating cancer clinically. Due to its
heterogeneous nature, complications of the chemoresistance mechanisms of breast cancer cannot
be completely elucidated. Existing mechanisms of main-line drug treatment can slow down the process
of malignancy with part and parcel called drug resistance. The combinatorial effect of several
chemotherapeutic drugs, targeting different pathways at the same time, can work efficiently, yet
the toxicity and drug-drug interaction remain intact.
To overcome this hurdle, a number of strategies have been discovered, such as novel agents, drug
carriers, and combination treatment, etc., which target mediated drug delivery systems; nanomedicine
and the use of phytocompounds can transfer the drug particularly to the cancerous cells
with minimal side effects to the neighboring healthy cells. The cell cycle checkpoint proteins and
genes induced to the deranged cells can inhibit the resistance mechanism towards the drug. Modification
of cell signaling pathways can also help to treat breast cancer chemoresistance mechanisms
in the long run. This article reviews the execution and onset of chemoresistance in various cancers
and discusses potential therapeutic approaches to deal with the resistance mechanism.
This review summarizes the possible mechanisms and signaling pathways causing chemoresistance
in breast cancer cell lines and discusses alternative therapy to overcome this issue under pre-clinical
and clinical infrastructure.